Neointimal Hyperplasia in Coronary Vein Grafts: Pathophysiology and Prevention of a Significant Clinical Problem


  • Johannes Bonatti
  • Alexander Oberhuber
  • Thomas Schachner
  • Yiping Zou
  • Angelika Hammerer-Lercher
  • Reinhard Mittermair
  • Guenther Laufer



Neointimal hyperplasia in aortocoronary vein grafts represents a significant problem that, by itself or by development of vein graft atherosclerosis, leads to the return of symptoms and to major adverse cardiac events after coronary artery bypass grafting. The main causes of neointimal hyperplasia are surgical trauma, intraoperative ischemia reperfusion injury, and implantation of a vein into the arterial circulation. All these pathogenetic factors cause a loss of protective endothelial mediators. The initiating steps lead to the induction of a significant inflammatory response and to the production of mitogenic factors in the vascular wall. DNA synthesis in vascular smooth muscle cells is markedly up-regulated, and intracellular signal transduction leads to transcription of immediate early genes, which causes an intense proliferative response. Vascular smooth muscle cells proliferate, migrate through the internal elastic lamina with the support of proteases, and transform from contractile-type into secretory-type cells. A thick layer of neointima is formed. The prevention of neointimal hyperplasia includes meticulous surgical technique, the choice of a large target vessel, and adequate intraoperative storage of the vein graft. Local intraoperative therapy of the implanted graft has been successfully tested in the experimental setting with a variety of substances that tackle different steps in the pathologic mechanism. Systemic pharmacologic therapy in clinical use primarily consists of the use of platelet inhibitors and anticoagulants. The transfer of experimental knowledge to bedside application has been slow. Gene therapy represents a promising field for the improved management of vein graft neointimal hyperplasia.


Allaire E, Clowes AW. 1997. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg 63:582-91.nAnastasiou N, Allen S, Paniagua R, Chester A, Yacoub M. 1997. Altered endothelial and smooth muscle cell reactivity caused by University of Wisconsin preservation solution in human saphenous vein. J Vasc Surg 25:713-21.nAngelini GD, Bryan AJ, Hunter S, Newby AC. 1992. A surgical technique that preserves human saphenous vein functional integrity. Ann Thorac Surg 53:871-4.nAngelini GD, Bryan AJ, Williams HM, Morgan R, Newby AC. 1990. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg 99:433-9.nAngelini GD, Christie MI, Bryan AJ, Lewis MJ. 1989. Surgical preparation impairs release of endothelium-derived relaxing factor from human saphenous vein. Ann Thorac Surg 48:417-20.nAscione R, Underwood MJ, Lloyd CT, Jeremy JY, Bryan AJ, Angelini GD. 2001. Clinical and angiographic outcome of different surgical strategies of bilateral internal mammary artery grafting. Ann Thorac Surg 72:959-65.nBach RG, Kern MJ, Donohue TJ, Aguirre FV, Caracciolo EA. 1993. Comparison of phasic blood flow velocity characteristics of arterial and venous coronary artery bypass conduits. Circulation 88:II-133-40.nBai H, Morishita R, Kida I, et al. 1998. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 5:761-9.nBarner HB, Fischer VW. 1990. Endothelial preservation in human saphenous veins harvested for coronary grafting. J Thorac Cardiovasc Surg 100:148-9.nBartlett FF, Rapp JH, Goldstone J, Ehrenfeld WK, Stoney RJ. 1987. Recurrent carotid stenosis: operative strategy and late results. J Vasc Surg 5:452-6.nBassiouny HS, White S, Glagov S, Choi E, Giddens DP, Zarins CK. 1992. Anastomotic intimal hyperplasia: mechanical injury or flow induced. J Vasc Surg 15:708-16nBatellier J, Wassef M, Merval R, Duriez M, Tedgui A. 1993. Protection from atherosclerosis in vein grafts by a rigid external support. Arterioscler Thromb 13:379-84.nCable DG, Caccitolo JA, Caplice N, et al. 1999. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 100:II-392-6.nCalcagno D, Bei M, Ross SA, Klein A, Foegh ML. 1992. Effects of estrogen on vein grafts. J Cardiovasc Surg (Torino) 33:579-84.nCalcagno D, Conte JV, Howell MH, Foegh ML. 1991. Peptide inhibition of neointimal hyperplasia in vein grafts. J Vasc Surg 13:475-9.nCambria RP, Ivarsson BL, Fallon JT, Abbott WM. 1992. Heparin fails to suppress intimal proliferation in experimental vein grafts. Surgery 111:424-9.nCampeau L, Enjalbert M, Lesperance J, et al. 1984. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 311:1329-32.nCampeau L, Lesperance J, Cordobe F. 1978. Aortocoronary saphenous vein bypass graft changes 5 to 7 years after surgery. Circulation 58:I-170-5.nCarrel A. 1983. Landmark article, Nov 14, 1908: results of the transplantation of blood vessels, organs and limbs: by Alexis Carrel. JAMA 250:944-53.nCataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E. 1993. Factors influencing 1-year patency of coronary artery saphenous vein grafts: Studio Indobufene nel Bypass Aortocoronarico (SINBA). Circulation 88:II-93-8.nCercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. 1990. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 66:1755-60.nChaikhouniA,CrawfordFA,KochelPJ,OlanoffLS,HalushkaPV.1986. Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Surg 92:88-91.nChaux A, Ruan XM, Fishbein MC, et al. 1998. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 115:604-12.nChen S, Gardner DG. 1998. Retinoic acid uses divergent mechanisms to activate or suppress mitogenesis in rat aortic smooth muscle cells. J Clin Invest 102:653-62.nChen SJ, Wilson JM, Muller DW. 1994. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 89:1922-8.nCherian SM, Bobryshev YV, Inder SJ, et al. 1999. Involvement of dendritic cells in long-term aortocoronary saphenous vein bypass graft failure. Cardiovasc Surg 7:508-18.nDilley RJ, McGeachie JK, Tennant M. 1992. The role of cell proliferation and migration in the development of a neo-intimal layer in veins grafted into arteries, in rats. Cell Tissue Res 269:281-7.nDregelid E, Svendsen E, Sandberg S. 1992. Hypoxia does not occur during temporary storage of vein grafts in air-equilibrated solutions. J Cardiovasc Surg (Torino) 33:143-8.nEhsan A, Mann MJ, Dell'Acqua G, Dzau VJ. 2001. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121:714-22.nFernandez HA, Kallenbach K, Seghezzi G, et al. 1998. Modulation of matrix metalloproteinase activity in human saphenous vein grafts using adenovirus-mediated gene transfer. Surgery 124:129-36.nFingerle J, Au YP, Clowes AW, Reidy MA. 1990. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 10:1082-7.nFitzGibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. 1996. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28:616-26.nKibbe MR, Tzeng E, Gleixner SL, et al. 2001. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34:156-65.nKohler TR, Kirkman TR, Clowes AW. 1989. The effect of rigid external support on vein graft adaptation to the arterial circulation. J Vasc Surg 9:277-85.nKown MH, Yamaguchi A, Jahncke CL, et al. 2001. L-arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 121:971-80.nLam JY, Solymoss BC, Campeau L. 1991. Platelets and thrombosis in vein graft occlusion: role and prevention. Cardiovasc Clin 21:67-81.nLeville CD, Dassow MS, Seabrook GR, Jean-Claude JM, Towne JB, Cambria RA. 2000. All-trans-retinoic acid decreases vein graft intimal hyperplasia and matrix metalloproteinase activity in vivo. J Surg Res 90:183-90.nLeville CD, Osipov VO, Jean-Claude JM, Seabrook GR, Towne JB, Cambria RA. 2000. All-trans-retinoic acid decreases cell proliferation and increases apoptosis in an animal model of vein bypass grafting. Surgery 128:178-84.nMatsumoto T, Komori K, Yonemitsu Y, et al. 1998. Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 27:135-44.nMcCann RL, Hagen PO, Fuchs JC. 1980. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg 191:238-43.nMoore S, Friedmann RJ, Singal DP, et al. 1976. Inhibition of injury induced thrombo-atherosclerotic lesions by anti-platelet serum in rabbits. Haemostasis 35:70-81.nMorishita R, Gibbons GH, Horiuchi M, et al. 1995. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 92:5855-9.nMotwani JG, Topol EJ. 1998. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97:916-31.nMurphy G, Docherty AJ. 1992. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120-5.nNunokawa Y, Tanaka S. 1992. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun 188:409-15.nNunokawa Y, Tanaka S. 1992. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun 188:409-15.nO'Donohoe MK, Schwartz LB, Radic ZS, Mikat EM, McCann RL, Hagen PO. 1991. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann Surg 214:727-32.nOhki T. 1993. Localized intimal hyperplasia in autologous vein graft: does presence of the valve induce obliteration? [in Japanese]. Nippon Geka Gakkai Zasshi 94:302-10.nOlson NE, Chao S, Lindner V, Reidy MA. 1992. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol 140:1017-23.nO'Neil GS, Chester AH, Schyns CJ, Tadjkarimi S, Borland JA, Yacoub MH. 1994. Effect of surgical preparation and arterialization on vasomotion of human saphenous vein. J Thorac Cardiovasc Surg 107:699-706.nOrtu P, LaMuraglia GM, Roberts WG, Flotte TJ, Hasan T. 1992. Photodynamic therapy of arteries: a novel approach for treatment of experimental intimal hyperplasia. Circulation 85:1189-96.nOtani H, Yamamura T, Nakao Y, et al. 2000. Vacuolar H-ATPase plays a crucial role in growth and phenotypic modulation of myofibroblasts in cultured human saphenous vein. Circulation 102:III-269-74.nPepper MS, Ferrara N, Orci L, Montesano R. 1991. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-6.nPertovaara L, Kaipainen A, Mustonen T, et al. 1994. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271-4.nPorter KE, Loftus IM, Peterson M, Bell PR, London NJ, Thompson MM. 1998. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br J Surg 85:1373-7.nPorter KE, Thompson MM, Loftus IM, et al. 1999. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 17:404-12.nGuzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. 1993. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 88:2838-48.nHagen PO, Davies MG, Schuman RW, Murray JJ. 1992. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 29:405-9.nHanna AK, Duran WN, Leconte I, et al. 2000. Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts. J Vasc Surg 31:770-80.nHansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. 1988. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res 63:712-9.nHata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. 1995. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch 426:479-86.nHayashi A, Suzuki T, Tajima S. 1995. Modulations of elastin expression and cell proliferation by retinoids in cultured vascular smooth muscle cells. J Biochem (Tokyo) 117:132-6.nBennett MR, Evan GI, Schwartz SM. 1995. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 95:2266-74.nBerguer R, Higgins RF, Reddy DJ. 1980. Intimal hyperplasia: an experimental study. Arch Surg 115:332-5. Berkowitz HD, Fox AD, Deaton DH. 1992. Reversed vein graft stenosis: early diagnosis and management. J Vasc Surg 15:130-41.nBhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. 2001. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103:363-8.nBobryshev YV, Farnsworth AE, Lord RS. 2001. Expression of vascular endothelial growth factor in aortocoronary saphenous vein bypass grafts. Cardiovasc Surg 9:492-8.nBonatti J, Dichtl W, Dworzak EA, et al. 1998. Atrial natriuretic peptide-induced release of cyclic guanosine monophosphate by coronary bypass grafts. Ann Thorac Surg 65:1621-4.nBonatti J, Dichtl W, Dworzak EA, et al. 1998. Stimulated prostacyclin release by conduits used for coronary artery bypass grafting. Thorac Cardiovasc Surg 46:59-62.nMann MJ, Whittemore AD, Donaldson MC, et al. 1999. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354:1493-8.nMann MJ, Whittemore AD, Donaldson MC, Belkin MA, Orav J, Polak J. 1997. Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition [abstract]. Circulation 96:I-4.nMannion JD, Ormont ML, Magno MG, O'Brien JE, Shi Y, Zalewski A. 1998. Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann Thorac Surg 66:1948-52.nMannion JD, Ormont ML, Shi Y, et al. 1998. Saphenous vein graft protection: effects of c-myc antisense. J Thorac Cardiovasc Surg 115:152-61.nMarch KL, Patton BL, Wilensky RL, Hathaway DR. 1993. 8-Methoxyp-soralen and longwave ultraviolet irradiation are a novel antiproliferative combination for vascular smooth muscle. Circulation 87:184-91.nMarin ML, Veith FJ, Panetta TF, et al. 1993. Saphenous vein biopsy: a predictor of vein graft failure. J Vasc Surg 18:407-14.nYamaguchi A, Woodburn KW, Hayase M, Robbins RC. 2000. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model. Circulation 102:III-275-80.nYang Z, Noll G, Luscher TF. 1993. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation 88:832-6.nYang Z, Oemar B, Luscher TF. 1993. Mechanism of coronary bypass graft disease [in German]. Schweiz Med Wochenschr 123:422-7.nYang Z, Ruschitzka F, Rabelink TJ, et al. 1997. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels: implications for venous bypass graft failure. Circulation 95:1870-6.nYang Z, von Segesser L, Turina M, Luscher TF, Wijns W. 1992. Pulsatile stretch and platelet-derived growth factor (PDGF): important mechanism for coronary venous graft disease [abstract]. Circulation 86:I.nZerkowski HR, Knocks M, Konerding MA, et al. 1993. Endothelial damage of the venous graft in CABG: influence of solutions used for storage and rinsing on endothelial function. Eur J Cardiothorac Surg 7:376-82.nBonatti J, Dichtl W, Lercher A, Puschendorf B. 2000. Natriuretic peptides stimulate cyclic guanosine monophosphate production in human saphenous vein and internal mammary artery. Eur J Cardiothorac Surg 17:175-81.nBourassa MG. 1991. Fate of venous grafts: the past, the present and the future. J Am Coll Cardiol 17:1081-3.nBrody WR, Angeli WW, Kosek JC. 1972. Histologic fate of the venous coronary artery bypass in dogs. Am J Pathol 66:111-30.nBrody WR, Brown JW, Reitz BA, Fry DL, Michaelis LL. 1977. Effects of dipyridamol and methylprednisolone on intimal thickening in vein grafts. J Thorac Cardiovasc Surg 73:601-4.nBrody WR, Kosek JC, Angell WW. 1972. Changes in vein grafts following aorto-coronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg 64:847-54.nBroeders MA, Doevendans PA, Maessen JG, et al. 2001. The human internal thoracic artery releases more nitric oxide in response to vascular endothelial growth factor than the human saphenous vein. J Thorac Cardiovasc Surg 122:305-9.nCucina A, Sapienza P, Corvino V, et al. 2000. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery 127:316-22.nDaemen MJ, Lombardi DM, Bosman FT, Schwartz SM. 1991. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-6.nDashwood MR, Mehta D, Izzat MB, et al. 1998. Distribution of endothelin-1 (ET) receptors (ET(A) and ET(B)) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis 137:233-42.nDattilo JB, Lust RM, Dattilo MP, et al. 1997. The temporal expression of transforming growth factor-b1 in early aortocoronary vein grafts. J Surg Res 69:349-53.nDavies AH, Magee TR, Baird RN, Sheffield E, Horrocks M. 1992. Vein compliance: a preoperative indicator of vein morphology and of veins at risk of vascular graft stenosis. Br J Surg 79:1019-21.nDavies MG, Barber L, Dalen H, Svendsen E, Hagen PO. 1994. Control of the structural and functional consequences of vein graft intimal hyperplasia with a 21-aminosteroid--U74389G. Eur J Vasc Surg 8:448-56.nGeorge SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. 2000. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101:296-304.nGorge G, Ge J, Erbel R. 1998. Role of intravascular ultrasound in the evaluation of mechanisms of coronary interventions and restenosis. Am J Cardiol 81:91G-5GnGrondin CM, Meere C, Castonguay Y, Lepage G, Grondin P. 1971. Progressive and late obstruction of an aorto-coronary venous bypass graft. Circulation 43:698-702.nGuarda E, Grez R, Irarrazabal MZ, Acevedo C. 1996. Effects of doxicycline on metalloproteinase activity of mammary arteries and saphenous veins [abstract]. Eur Heart J 17:103.nGuerin E, Ludwig MG, Basset P, Anglard P. 1997. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid: therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1-mediated transrepression. J Biol Chem 272:11088-95.nGundry SR, Jones M, Ishihara T, Ferrans VJ. 1980. Intraoperative trauma to human saphenous veins: scanning electron microscopic comparison of preparation techniques. Ann Thorac Surg 30:40-7.nGunen E, Trubel W, Schwarzacher S, et al. 1999. Evaluation of distal anastomotic intimal hyperplasia: an experimental comparison by arteriography, duplex sonography, angioscopy, and intravascular ultrasound. Eur Surg Res 31:64-73.nNabel EG, Yang Z, Liptay S, et al. 1993. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest 91:1822-9.nNewby AC, George SJ. 1993. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 27:1173-83.nNguyen HC, Grossi EA, LeBoutillier M III, et al. 1994. Mammary artery versus saphenous vein grafts: assessment of basic fibroblast growth factor receptors. Ann Thorac Surg 58:308-10.nNiimi Y, Azuma H, Hirakawa K. 1994. Repeated endothelial removal augments intimal thickening and attenuates EDRF release. Am J Physiol 266:H1348-56.nNikkari ST, Jarvelainen HT, Wight TN, Ferguson M, Clowes AW. 1994. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol 144:1348-56.nNoris M, Morigi M, Donadelli R, et al. 1995. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 76:536-43.nHirko MK, McShannic JR, Schmidt SP, et al. 1993. Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts. J Vasc Surg 17:877-87.nHoch JR, Stark VK, Hullett DA, Turnipseed WD. 1994. Vein graft intimal hyperplasia: leukocytes and cytokine gene expression. Surgery 116:463-70.nHolt CM, Francis SE, Newby AC, et al. 1993. Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery. Ann Thorac Surg 55:1522-8.nHsieh HJ, Li NQ, Frangos JA. 1992. Shear-induced platelet-derived growth factor gene expression in human endothelial cells is mediated by protein kinase C. J Cell Physiol 150:552-8.nHu Y, Zou Y, Dietrich H, Wick G, Xu Q. 1999. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 100:861-8.nHughes SE, Hall PA. 1993. Overview of the fibroblast growth factor and receptor families: complexity, functional diversity, and implications for future cardiovascular research. Cardiovasc Res 27:1199-203.nHuynh TT, Davies MG, Barber L, Svendsen E, Hagen PO. 1998. Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts. J Surg Res 77:104-11.nIzzat MB, Mehta D, Bryan AJ, Reeves B, Newby AC, Angelini GD. 1996. Influence of external stent size on early medial and neointimal thickening in a pig model of saphenous vein bypass grafting. Circulation 94:1741-5.nJackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75:1205-10.nKalan JM, Roberts WC. 1990. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J 119:1164-84.nKalra M, Miller VM. 2000. Early remodeling of saphenous vein grafts: proliferation, migration and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J Vasc Res 37:576-84.nLibby P, Warner SJ, Salomon RN, Birinyi LK. 1988. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 318:1493-8.nLimanni A, Fleming T, Molina R, et al. 1988. Expression of genes for platelet-derived growth factor in adult human venous endothelium: a possible non-platelet-dependent cause of intimal hyperplasia in vein grafts and perianastomotic areas of vascular prostheses. J Vasc Surg 7:10-20.nLimet R, David JL, Magotteaux P, Larock MP, Rigo P. 1987. Prevention of aorta-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 94:773-83.nLiu ZG, Ge ZD, He GW. 2000. Difference in endothelium-derived hyperpolarizing factor-mediated hyperpolarization and nitric oxide release between human internal mammary artery and saphenous vein. Circulation 102:III-296-301.nLoGerfo FW, Quist WC, Cantelmo NL, Haudenschild CC. 1983. Integrity of vein grafts as a function of initial intimal and medial preservation. Circulation 68:II-117-24.nLoop FD, Lytle BW, Cosgrove DM, Golding LA, Taylor PC, Stewart RW. 1986. Free (aorta-coronary) internal mammary artery graft: late results. J Thorac Cardiovasc Surg 92:827-31.nLuo Z, Asahara T, Tsurumi Y, Isner JM, Symes JF. 1998. Reduction of vein graft intimal hyperplasia and preservation of endothelium-dependent relaxation by topical vascular endothelial growth factor. J Vasc Surg 27:167-73.nLuscher TF, Diederich D, Siebenmann R, et al. 1988. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319:462-7.nMajesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. 1991. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 88:904-10.nMajesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. 1990. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 111:2149-58.nMalone JM, Kischer CW, Moore WS. 1981. Changes in venous endothelial fibrinolytic activity and histology with in vitro venous distention and arterial implantation. Am J Surg 142:178-82.nMangi AA, Dzau VJ. 2001. Gene therapy for human bypass grafts. Ann Med 33:153-5.nMann MJ, Gibbons GH, Hutchinson H, et al. 1999. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 96:6411-6.nMann MJ, Gibbons GH, Kernoff RS, et al. 1995. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 92:4502-6.nPredel HG, Yang Z, von Segesser L, Turina M, Buhler FR, Luscher TF. 1992. Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet 340:878-9.nQuist WC, LoGerfo FW. 1992. Prevention of smooth muscle cell phenotypic modulation in vein grafts: a histomorphometric study. J Vasc Surg 16:225-31.nRajah SM, Nair U, Rees M, et al. 1994. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 107:1146-53.nRao GN, Berk BC. 1992. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70:593-9nRoss R, Glomset J, Kariya B, Harker L. 1974. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 71:1207-10.nRoth JA, Cukingnan RA, Brown BG, Gocka E, Carey JS. 1979. Factors influencing patency of saphenous vein grafts. Ann Thorac Surg 28:176-83.nZilla P, von Oppell U, Deutsch M. 1993. The endothelium: a key to the future. J Card Surg 8:32-60.nZou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q. 1998. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol 153:1301-10.nZou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q. 2000. Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 86:434-40.nZurbrugg HR, Knollmann F, Musci M, et al. 2000. The biocompound method in coronary artery bypass operations: surgical technique and 3-year patency. Ann Thorac Surg 70:1536-40.nZweep HP, Satoh S, van der Lei B, et al. 1993. Autologous vein supported with a biodegradable prosthesis for arterial grafting. Ann Thorac Surg 55:427-33.nZwolak RM, Adams MC, Clowes AW. 1987. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 5:126-36.nChervu A, Moore WS. 1990. An overview of intimal hyperplasia. Surg Gynecol Obstet 171:433-47.nChervu A, Moore WS, Quinones-Baldrich WJ, Henderson T. 1989. Efficacy of corticosteroids in suppression of intimal hyperplasia. J Vasc Surg 10:129-34.nChester AH, O'Neil GS, Tadjakarimi S, Borland JA, Yacoub MH. 1993. Effect of peri-operative storage solution on the vascular reactivity of the human saphenous vein. Eur J Cardiothorac Surg 7:399-404.nClark SD, Kobayashi DK, Welgus HG. 1987. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 80:1280-8.nClowes AW, Clowes MM, Reidy MA. 1986. Kinetics of cellular proliferation after arterial injury, III: endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest 54:295-303.nCox JL, Chiasson DA, Gotlieb AI. 1991. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 34:45-68.nDavies MG, Dalen H, Barber L, Svendsen E, Hagen PO. 1996. Lazaroid therapy (methylaminochroman: U83836E) reduces vein graft intimal hyperplasia. J Surg Res 63:128-36.nDavies MG, Fulton GJ, Svendsen E, Hagen PO. 1999. Time course of the regression of intimal hyperplasia in experimental vein grafts. Cardiovasc Pathol 8:161-8.nDavies MG, Hagen PO. 1995. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 9:7-18.nDavies MG, Kim JH, Dalen H, Makhoul RG, Svendsen E, Hagen PO. 1994. Reduction of experimental vein graft intimal hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine. Surgery 116:557-68.nDavies MG, Klyachkin ML, Dalen H, Massey MF, Svendsen E, Hagen PO. 1993. The integrity of experimental vein graft endothelium: implications on the etiology of early graft failure. Eur J Vasc Surg 7:156-65.nDiCorleto PE, Chisolm GM III. 1986. Participation of the endothelium in the development of the atherosclerotic plaque. Prog Lipid Res 25:365-74.nFoegh ML, Virmani R. 1994. Molecular biology of intimal proliferation. In: Yacoist M, Popper J, editors. Annual of cardiac surgery. London, UK: Current Science Ltd. p 63-5. Fonkalsrud EW, Sanchez M, Zerubavel R. 1978. Morphological evaluation of canine autogeneous vein grafts in the arterial circulation. Surgery 84:253-64.nFrancis SE, Holt CM, Taylor T, Gadsdon P, Angelini GD. 1992. Heparin and neointimal thickening in an organ culture of human saphenous vein [letter]. Atherosclerosis 93:155-6.nFrancis SE, Hunter S, Holt CM, et al. 1994. Release of platelet-derived growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg 108:540-8.nFulton GJ, Davies MG, Koch WJ, Dalen H, Svendsen E, Hagen PO. 1997. Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts. J Vasc Surg 25:453-63.nGeorge SJ, Angelini GD, Capogrossi MC, Baker AH. 2001. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 8:668-76.nGeorge SJ, Baker AH, Angelini GD, Newby AC. 1998. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 5:1552-60.nShi Y, O'Brien JE Jr, Mannion JD, et al. 1997. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation 95:2684-93.nSidawy AN, Hakim FS, Neville RF, Korman LY. 1993. Autoradiographic mapping and characterization of insulin-like growth factor-I receptor binding in human greater saphenous vein. J Vasc Surg 18:947-52.nSnow AD, Bolender RP, Wight TN, Clowes AW. 1990. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 137:313-30.nSolberg S, Larsen T, Jorgensen L, Sorlie D. 1987. Cold induced endothelial cell detachment in human saphenous vein grafts. J Cardiovasc Surg (Torino) 28:571-5.nSolymoss BC, Leung TK, Pelletier LC, Campeau L. 1991. Pathologic changes in coronary artery saphenous vein grafts and related etiologic factors. Cardiovasc Clin 21:45-65.nSottiurai VS, Yao JS, Flinn WR, Batson RC. 1983. Intimal hyperplasia and neointima: an ultrastructural analysis of thrombosed grafts in humans. Surgery 93:809-17.nSoyombo AA, Angelini GD, Bryan AJ, Newby AC. 1993. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res 27:1961-7.nStavri GT, Hong Y, Zachary IC, et al. 1995. Hypoxia and platelet-derived growth factor-BB synergistically upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 358:311-5.nStavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. 1995. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 92:11-4.nStein PD, Dalen JE, Goldman S, Theroux P. 2001. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 119:278S-82S.nSubramanian VA, Hernandez Y, Tack Goldman K, Grabowski EF, Weksler BB. 1986. Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery 100:376-83.nSuggs WD, Olson SC, Madnani D, Patel S, Veith FJ, Mandani D. 1999. Antisense oligonucleotides to c-fos and c-jun inhibit intimal thickening in a rat vein graft model. Surgery 126:443-9.nSuzuki T, Kopia G, Hayashi S, et al. 2001. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-93.nTaggart DP, D'Amico R, Altman DG. 2001. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 358:870-5.nTakeshita S, Gal D, Leclerc G, et al. 1994. Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation: in vitro and in vivo findings in a rabbit model of vascular injury. J Clin Invest 93:652-61.nThiene G, Miazzi P, Valsecchi M, et al. 1980. Histological survey of the saphenous vein before its use as autologous aortocoronary bypass graft. Thorax 35:519-22.nToes GJ, Barnathan ES, Liu H, et al. 1996. Inhibition of vein graft intimal and medial thickening by periadventitial application of a sulfated carbohydrate polymer. J Vasc Surg 23:650-6.nUnderwood MJ, More R, Weeresena N, Firmin RK, De Bono DP. 1993. The effect of surgical preparation and in-vitro distension on the intrinsicfibrinolytic activity of human saphenous vein. Eur J Vasc Surg 7:518-22.nVerrier ED, Boyle EM Jr. 1996. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 62:915-22.nViswanathan M, Stromberg C, Seltzer A, Saavedra JM. 1992. Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. J Clin Invest 90:1707-12.nWalker LN, Bowen-Pope DF, Ross R, Reidy MA. 1986. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci U S A 83:7311-5.nWaller BF, Roberts WC. 1985. Remnant saphenous veins after aortocoronary bypass grafting: analysis of 3,394 centimeters of unused vein from 402 patients. Am J Cardiol 55:65-71.nSanchez AM, Wooldridge TA, Boerboom LE, Olinger GN, Almassi GH, Rusch NJ. 1994. Comparison of saphenous vein graft relaxation between Plasma-Lyte solution and normal saline solution. J Thorac Cardiovasc Surg 107:1445-53.nSantoli E, Di Mattia D, Boldorini R, Mingoli A, Tosoni A, Santoli C. 1993. University of Wisconsin solution and human saphenous vein graft preservation: preliminary anatomic report. Eur J Cardiothorac Surg 7:548-52.nSchachner T, Zou Y, Oberhuber A, et al. 2004. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. In press.nSchwartz LB, Moawad J, Svensson EC, et al. 1999. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 29:874-81.nSchwartz SM, deBlois D, O'Brien ER. 1995. The intima: soil for atherosclerosis and restenosis. Circ Res 77:445-65.nSenger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. 1997. Angiogenesis promoted by vascular endothelial growth factor: regulation through a 1 band a 2 bintegrins. Proc Natl Acad Sci U S A 94:13612-7.nSergeant P, Blackstone E, Meyns B. 1997. Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG: K.U. Leuven Coronary Surgery Program. Eur J Cardiothorac Surg 12:1-19.nWang H, Li Z, Moore S, Alavi MZ. 1998. Collagen biosynthesis by neointimal smooth muscle cells cultured from rabbit aortic explants 15 weeks after de-endothelialization. Int J Exp Pathol 79:47-53.nWaters DJ, Thomsen TA. 1993. Saphenous vein preparation for coronary artery bypass grafting using a cardioplegia delivery set. Ann Thorac Surg 56:385-6.nWeintraub WS, Jones EL, Craver JM, Guyton RA. 1994. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 73:103-12.nWeissberg PL, Grainger DJ, Shanahan CM, Metcalfe JC. 1993. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res 27:1191-8.nWillard JE, Netto D, Demian SE, et al. 1992. Intravascular ultrasound imaging of saphenous vein grafts in vitro: comparison with histologic and quantitative angiographic findings. J Am Coll Cardiol 19:759-64.nWilson NV, Salisbury JR, Kakkar VV. 1994. The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg 8:60-4.nSoyombo AA, Angelini GD, Newby AC. 1995. Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J Thorac Cardiovasc Surg 109:2-12.nStark VK, Hoch JR, Warner TF, Hullett DA. 1997. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 17:1614-21.nStary HC, Blankenhorn DH, Chandler AB, et al. 1992. A definition of the intima of human arteries and of its atherosclerosis- prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 85:391-405.n



How to Cite

Bonatti, J., Oberhuber, A., Schachner, T., Zou, Y., Hammerer-Lercher, A., Mittermair, R., & Laufer, G. (2005). Neointimal Hyperplasia in Coronary Vein Grafts: Pathophysiology and Prevention of a Significant Clinical Problem. The Heart Surgery Forum, 7(1), E72-E87.




Most read articles by the same author(s)

1 2 3 4 > >>